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. DAB2IP interacts with CDC20. (A) IF staining showed that DAB2IP overlaps with kinetochore marker crest during mitosis. (B) IP experiment revealed that DAB2IP could interact with CDC20 and Cdc27. (C) Immunoassay of 293T cells co-transfected with vectors expressing HA-tagged Cdc20 and Flag-tagged deletion mutants of DAB2IP; cells were treated with nocodazole, lysates were immunoprecipitated with anti-Flag M2 beads and immunoprecipitates were probed with an anti-HA or anti-Flag antibody 6 prometaphase and treated with cycloheximide for different time. Notably, the rate of this proteolysis was slowed down in DAB2IP proficient C4-2 cells (Figure 3 ).
DAB2IP is required for chromosome segregation and chromosomal stability maintenance:
The defect of SAC is one of the main reasons leading to chromosomal instability, which was a hallmarker and driving force for the tumor progression. We next detected whether the DAB2IP contributes to chromosomal stability maintenance. Firstly, we examined the chromosome movements in C4-2 cells through an unchallenged mitosis. We found that the percentage of cells with lagging chromosomes markedly decreased in DAB2IP-expressing cells. Using flow cytometry and chromosome spread methods, we also identified that DAB2IP could dramatically inhibited the increase of aneuploidy cells. As mentioned in our last year's report, that we have already standardized the conditions to develop prostate orthotopic model in rats and published our findings in the Journal of International of Oncology. However, we have encountered several problems that hindered the timely progress in finishing the specific aim 3 in a timely manner. Therefore, we have requested no cost extension and here is what we wrote in an email on May 23, 2014 to the members of the DOD PCRP "The results among the treatment groups are not consistent because of imaging issues. Since the primary readout is bioluminescence signal from the tumor produing cells and we have some problem with the optimal time of acquisition of the signal and the tumor growth. We found that problem is in the PCa cell lines which transfected with Luciferase cell line. Therefore, we are testeng the different clones of this recombinant cell before we implant into the animals. We are cofident that we will be able to finish all the proposed studies within the extended period as requested".
However we are continuing working on Task 9 and below are some of the results: We implanted PC3KD-luc cells orthotopically inside the prostate of adult male nude rats and using ultrasound as the primary tumor measurement tool instead of BLI to monitor the tumor progression. Tumors were radiated with 3 fractions of 12 Gy. We found the irradiation (3 X 12Gy) had a significant impact on tumor growth ( Figure 5 , A-C).
We also observed the irradiation treatment of 3 X 12Gy causes GI tract toxicity as shown in Figure 6 in some animals. In order to minimize the toxicity of irradiation, we will combine the radiation treatment with NU7441 and will be performed during the extension period. 
The work to be completed during the no cost extension period (Task 10 and 11):
Mostly the experiments proposed in the Aim 3 in the original proposal will be performed. Briefly;
To determine the efficacy of the combined treatment, we will establish these groups (1) control, (2) radiation (12Gyx3), (3) radiation (12Gyx2), (4) radiation (12Gyx1), (5) NU7441 (25mg/kg), (6) NU7441+radiation (12Gyx3), (7) NU7441+radiation (12Gyx2), (8) NU7441+radiation (12Gyx2). We will measure the tumor volume using the Ultra Sound guided (USG) imaging and bioluminescence imaging (BLI). For Immunohistological analysis, we will establish similar animal groups and collect the tumor samples at different time points after treatment for (i) pimonidazole staining, (ii) HIF-1α expression level, (iii) Ki 67 staining (proliferation), (iv) γH2AX staining (For DNA damage/repair response) (v) DNA-PKcs staining (to differentiate normal and tumor tissue) and (v) Apoptosis Study. We will also analyze the radiation induced damage to the adjacent organs bladder and rectum by histology.
Task 12: This is our 3 rd and final progress report. Currently, we are finalizing our manuscripts on the experiments performed under Task 7. We are expecting 2 manuscripts on these novel findings. So far we have published 4 articles in peer reviewed journals and 2 under preparation. . Identification of patients who are most likely to have poor outcomes despite dose-escalated radiation therapy with long-term androgen deprivation can be challenging. Being able to predict the patients that portend worse outcome at the time of diagnosis may provide means to offer patients an alternative, more-effective therapy, possibly through the auspices of a clinical trial. Multiple biomarkers have been studied in the setting of high-risk prostate cancer (8, 9) , and although some have shown much promise, routine use of such markers in clinical practice has been limited (10) . Additional biomarkers that can readily identify patients most likely to fail conventional therapy are warranted, and investigations of the molecular pathway involved in this poor outcome may further lead to future therapeutic interventions.
DOC-2/DAB2 Interacting Protein (DAB2IP), a member of the Ras GTPase-Activating Proteins (RAS-GAP) family, is a novel tumor suppressor. Decreased expression of DAB2IP is often detected in prostate cancer cells, and this loss of DAB2IP is primarily due to altered epigenetic regulation of its promoter (11) . A genome-wide screening of single nucleotide polymorphisms indicated that a genetic variant in DAB2IP is linked with aggressive prostate cancer (12) . Furthermore, a population-based caseecontrol study confirmed that DAB2IP was linked with an increased risk of aggressive prostate cancer (12) . Immunohistochemistry analysis of more than 200 patients with prostate cancer by Min et al (13) clearly demonstrated the causal role of DAB2IP loss in prostate cancer progression. The aggressive nature of DAB2IP-deficient tumors is explained by recent cell culture model studies, which have found that loss of DAB2IP can lead to radiation resistance, increased DNA repair ability, and decreased apoptosis after radiation (14-16).
Enhancer of zeste homolog 2 (EZH2), the catalytic unit of the polycomb repressor complex, is often up-regulated in several cancers, including breast, lung, and prostate (17) . Our data indicate that DAB2IP is an EZH2 target gene in prostate cancer (18) . Overexpression of EZH2 has been shown to drive prostate cancer progression, and studies have shown that clinically localized tumors that express high levels of EZH2 have poorer outcomes (19, 20) . Additionally, it has been shown that in low-risk tumors EZH2 expression has been correlated with poor surgical outcomes (19) .
Although several cell culture and animal-based models have shown that DAB2IP and EZH2 are involved with increased radiation resistance (14, 15, 21) , there is no study that evaluates the clinical relevance of DAB2IP-mediated radiation resistance. Therefore, we sought to determine the prognostic value of DAB2IP and its upstream regulator EZH2 in high-risk prostate cancer patients.
Methods and Materials

Patient selection
All patients with prostate cancer treated with external beam radiation at our institution between December 2005 and July 2012 were identified. Of the 658 patients identified, 138 patients met the National Comprehensive Cancer Network guidelines for high-risk classification (stage T3a, or Gleason score 8, or PSA 20 ng/mL) and did not receive any surgical management. Patients who had metastases before initial radiation therapy were excluded from the study. All patients were treated definitively with external beam radiation therapy using a variety of techniques, including dynamic arc therapy; all patients were treated with a dose exceeding 72 Gy, and 80% were treated to 79.2 Gy. Of the 138 patients identified, only those patients who provided signed consent, who had preserved pretreatment prostate biopsy tissue available, and whose biopsies had a sufficient tumor sample available for analysis were included in the study.
Specimen characteristics, staining, and quantification
Diagnostic needle biopsies were mounted in paraffin, and 3-to 4-mm sections were prepared for standard hematoxylin and eosin staining. Standard immunohistochemistry analysis was performed for DAP2IP and EZH2. Immunostain was performed using the Benchmark XT automated stainer (Ventana, Tuscan, AZ). Briefly, formalin-fixed, paraffin-embedded tissue microarray sections were cut at 3-4 mm and air-dried overnight. The sections were deparaffinized, rehydrated, subjected to heat-induced epitope retrieval, and then incubated with anti-EZH2 (clone: SP129, Ventana, prediluted) or anti-DAB2IP (22) (homegrown, 1:150) primary antibodies. The UltraView universal detection system (Ventana) was used for signal detection. The slides were developed using 3-3 0 -diaminobenzidine chromogen and counterstained with hematoxylin. Specific positive and negative (slides incubated without primary antibody) controls were used for each run of immunostains and checked for validation of the assay. Controls for anti-EZH2 antibody included tissue from prostate and breast adenocarcinoma and normal lymph node that are known to have high EZH2 expression. The anti-EZH2 protocol was standardized according to the directions in the package insert. This antibody is intended for in vitro diagnostic use. The protocol for anti-DAP2IP was performed as previously reported (22) .
Tumor and benign prostate tissue stained with each marker were evaluated by an experienced genitourinary pathologist who was blinded to patient clinical information. Each case was evaluated for the extent (percentage of positive cells) and intensity of staining. The average intensity of positive tumor cells was given a grade (G) score: G0, none; G1, weak; G2, intermediate; and G3, strong. The DAB2IP positivity was evaluated as cytoplasmic expression; EZH2 was evaluated as nuclear pattern of expression. Compared with DAB2IP expression in the benign "control" prostate tissue surrounding the neoplastic cells, tumor DAB2IP status was categorized as retained (same or stronger expression) or reduced (weaker expression). Expression of EZH2 was scored as the product of percentage of cells staining and the intensity of staining.
Study design
The 3 primary clinical endpoints in this study were freedom from biochemical failure (FFBF), castration resistancee free survival (CRFS), and distant metastasisefree survival (DMFS). Freedom from biochemical failure was determined using the Phoenix definition, which denotes a PSA increase of 2.0 ng/mL above the nadir PSA level (23) . Castration resistanceefree survival was defined as 2 episodes of rising PSA while receiving standard hormone therapy in the setting of testosterone levels <50 ng/mL, or if patients were started on second-line therapy because firstline hormone therapy was deemed to have failed at the clinical oncologist's discretion. Distant metastasisefree survival was determined from clinical chart review documenting date of known metastasis by imaging. Time to each endpoint was calculated from the first day of radiation therapy.
Statistical analysis
In this study there were 2 main biomarkers: DAB2IP and EZH2. A 2-sided log-rank test with an overall sample size of 46 for DAB2IP and 48 for EZH2 achieves 80% power at a 0.025 significance level to detect a significant difference in 4-year FFBF rates between the 2 groups. The sample size estimation was conducted using the sample size software PASS 11(NCSS, Kaysville, Utah). Kaplan-Meier estimates and log-rank tests were computed to estimate the FFBF, CRFS, and DMFS. Univariate Cox regression analysis of T stage, N stage, highest Gleason score, pretreatment PSA level, percentage of positive biopsy cores, total radiation dose, hormone therapy, and duration of hormone therapy was performed. Finally, Fisher exact test was used to evaluate statistical differences among these factors according to the status of the tumor biomarkers.
Results
Fifty-four patients with high-risk prostate cancer treated with definitive radiation therapy from 2005 to 2012 met the inclusion criteria and were evaluated. The median age of patients used for analysis was 66 years. Twenty-eight percent of patients (13 of 46) revealed DAB2IP reduction, whereas 72% (33 of 46) retained DAB2IP. Nearly all patients expressed EZH2 (98%), and the intensity level was G0 in 1 (2%), G1 in 9 (19%), G2 in 29 (60%), and G3 in 9 (19%) patients. The median pretreatment PSA level was 14.8 ng/mL (range, 1.2-208.9 ng/mL). Gleason scores were 7 in 22% of patients and 8-10 in 78% of patients. Clinical T stage category was T1c in 19% of patients, T2a-c in 56% of patients, and T3a-b in 22% of patients. Table 1 displays a distribution of patient characteristics.
The median follow-up was 34.0 months (range, 6.7-76.1 months) for DAB2IP-reduced patients, 29.9 months (range, 6.1-84.6 months) for DAB2IP-retained patients, and 32.6 months (range, 2.8-84.6 months) for patients in the EZH2 study. In the DAB2IP study there was no statistically significant difference between use of hormone therapy (PZ.55) or duration of hormone therapy (PZ.63). Of the patients in the EZH2 study who received hormone therapy, there was no significant difference in duration (PZ.81).
Interestingly, reduction of DAB2IP in patient's prostate cancer samples correlated strongly with several poor outcome measures. Reduction of DAB2IP portended a significantly lower FFBF ( Fig. 1A ; PZ.04) and increased likelihood of progression to castration resistance (PZ.017). Patients with reduced DAB2IP compared with patients retaining DAB2IP had a 4-year FFBF of 37% and 89%, respectively. The 4-year CRFS for DAB2IP-reduced patients was 50%, whereas the 4-year CRFS was 90% for DAB2IP-retained patients. Loss of DAB2IP was not a statistically significant predictor of increased distant metastasis (PZ.05), although it trended toward significance. Increased follow-up or a larger data set will most likely result in a significant outcome. The 4-year DMFS was 36% for DAB2IP-reduced patients and 97% for DAB2IP-retained patients. Median time to biochemical failure was 29.7 months and 23.7 months for the DAB2IP-retained and -reduced groups, respectively. The median time to castration resistance was 29.9 months and 27.6 months, whereas the median time to distant failure was 29.9 months and 26.7 months for the DAB2IPretained and -reduced groups, respectively.
Analysis of EZH2 samples shows that nearly all highrisk patients exhibit expression of EZH2 (98%). Stratification of EZH2 expression was not significantly predictive of decreased FFBF ( Fig. 1B ; PZ.07), increased castration resistance (PZ.07), or decreased distant metastasis rate (PZ.2), although it trended toward significance.
It is interesting to note, however, that combining patients who had either EZH2 G3 staining or decreased DAB2IP levels created a group found to have significantly worse outcomes. The 4-year FFBF for this combined group compared with the control group (retained DAB2IP and EZH2 G0-G2) was 32% versus 95% ( Fig. 1C ; PZ.0153), the 4-year CRFS was 28% versus 100% (PZ.0019), and the 4-year DMFS was 39% versus 100% (PZ.04), respectively. Additionally, the combined group of DAB2IPreduced or EZH2 G3 patients accounted for 6 of the 7 patients (86%) who were identified to have clinical castration resistance. Table 2 summarizes all patient outcomes by tumor biomarker status.
Of the 7 patients with castration resistance, their initial androgen deprivation therapy was leuprolide, except for 1 patient who chose orchiectomy. Five of the patients had testosterone levels measured within 1 year before developing castration resistance, and the remaining 2 patients did not have any serum testosterone levels recorded in their medical records. The 5 patients with serum testosterone data had the following levels immediately before or on the day they were determined to have castration resistance: 3.7, 9, <12, 19, and 58 ng/mL. The patient with the testosterone level of 58 ng/mL as well as the 2 patients without measured testosterone levels were determined to have clinical evidence of castration resistance because of a continual rise in PSA despite adding a second agent to their androgen deprivation therapy.
Univariate analysis using Cox regression of typical prognostic variables versus FFBF revealed that only the highest Gleason score (PZ.0290) was statistically significant ( Table 3 ). The EZH2 grade (PZ.07) trended toward significance. Although tumor DAB2IP status was nearly significant by Cox regression (PZ.055), as stated earlier the log-rank test for DAB2IP versus FFBF was significant (PZ.04). Further analysis showed that reduction of DAB2IP is strongly correlated with increasing Gleason score ( Fig. 2 ; PZ.0087), suggesting that DAB2IP reduction leads to more aggressive phenotypes of prostate cancer.
Discussion
Disabled homolog 2-interacting protein, a tumor suppressor and member of the RAS-GAP family, has been linked with an increased risk of aggressive cancer (12) . Although the exact function of DAB2IP has yet to be determined, studies have shown that loss of DAB2IP leads to hyper-activation of the PI3K-AKT axis (16) . Disabled homolog 2interacting proteinedeficient cell lines are more resistant to ionizing radiation owing an increased ability to repair double-strand DNA breaks and promote robust G2/M cell cycle arrest (14, 21) . Furthermore, cells that lack DAB2IP are more likely to undergo autophagy, rather than apoptosis, in response to ionizing radiation (15) . On the basis of strong preclinical data indicating the role of DAB2IP in radiation response in prostate cancer cells, we sought to determine its clinical impact (15) . However, the tumor environment is a complex milieu with multiple interacting activators and inhibitors. Therefore, in addition to studying DAB2IP, we also sought to determine the potential prognostic role of its upstream regulator, EZH2, in high-risk prostate cancer patients treated with radiation therapy.
In this pilot study we show that DAB2IP status and not EZH2 seems to correlate with earlier biochemical failure rates after treatment with definitive radiation therapy in high-risk prostate cancer patients. Interestingly, we found that nearly all high-risk prostate cancer samples in this study express high levels of EZH2, confirming the notion that increased EZH2 precedes loss of DAB2IP. Our results are concordant with previous studies that show increased levels of EZH2 portend a poorer outcome, or more specifically, increased EZH2 levels can predict high-risk prostate cancer. It is worth emphasizing that the trend toward worse outcomes occurred despite patients with higher EZH2 levels having been significantly more likely to receive hormone therapy (PZ.0417). Varambally et al (20) noted that EZH2 G3 staining or greater was associated with increased clinical failure (31%), whereas significantly fewer patients (9%) with low-intensity staining had clinical failure. Although the patients evaluated in Varambally's study received surgical management and not radiation, the results support the conclusions presented here.
Rather than predict cancers with poor therapeutic response, EZH2 levels may help screen for higher-risk cancers. In addition, it is possible that if the cohort were expanded to include all prostate cancer patients (including low-and intermediate-risk patients), then EZH2 will likely gain significance, and it may serve as an earlier marker of tumors that may have propensity toward high-risk differentiation. However, within the high-risk cohort of patients, DAB2IP seems to be a more suitable prognostic marker because it seems to be able to discriminate out the very worst players among this locally advanced aggressive prostate cancer group. We postulate that the higher the intensity of EZH2 staining, the more likely a tumor is to have decreased DAB2IP expression, and thus the more likely a patient is to have poor outcome. This theory is the logic behind using the "or" in our combined grouping system: that perhaps tumors with EZH2 G3 and retained DAB2IP will eventually manifest future DAB2IP loss and consequently become more aggressive.
There have been numerous studies into the use of biomarkers in prostate cancer, and although most are used for the evaluation of surgical patients, several studies have studied markers of radiation outcomes. The most successful studies have examined markers such as Ki-67, Bax, BCL-2, and BCL-xL, which are markers of apoptosis (8, 9) . However, results from these studies are heterogeneous and conflicting. DAB2IP protein may be better able to differentiate the worst cases among the already high-risk group of prostate cancer patients. In this pilot study, DAB2IP seems to be a significant prognostic indicator of failure after radiation therapy; however, DAB2IP requires further studies to validate its role in this cohort of patients and to further determine whether it may also be a predictive marker of response to radiation therapy. Limitations of this study include the small sample size, short follow-up for patients with EZH2 G0 and G3, and the fact that not all 54 patients had adequate biopsy samples to be analyzed for both DAB2IP and EZH2. With increased sample size and longer follow-up, it is possible that stratified EZH2 expression may also be a useful and statistically significant prognostic biomarker. Because this is a pilot study, a prospective validation study with a larger sample size is warranted.
We report that loss of DAB2IP may predict worse FFBF and increased likelihood of progression to castration resistance. Decreased FFBF in DAB2IP-deficient cells may be explained by dysregulation of survival pathways in response to ionizing radiation as described in several preclinical models. In addition, high Gleason scores correlate with a loss of DAB2IP. These findings may indicate that loss of DAB2IP may be a driver of prostate cancer progression, or alternatively that DAB2IP loss may be a hallmark for aggressive prostate cancer behavior. A recently published study determined that androgen binding decreases EZH2 level with a concomitant increase in DAB2IP level (24) , which is consistent with our previous observation that DAB2IP is a target gene of EZH2 in prostate cancer (18) . Another study found that DAB2IP expression was inversely related to androgen receptor activation in an androgen-independent manner (25) . The potential relation of DAB2IP to castration resistance may suggest an interaction of DAB2IP or its downstream proteins with the androgen receptor or interactions with androgen receptor elements.
As a prognostic biomarker, DAB2IP may identify patients at highest risk for treatment failure before initiation of standard therapy. Potential clinical application is that in the future we may be able to effectively use DAB2IP presence or absence from a patient's biopsy specimen as a means of determining curability of their cancer with standard radiation-based therapeutic regimens. Additionally, the DAB2IP pathway may be a potential target for improving treatment outcome and radiation response. Future research may be directed toward creating molecularly based therapeutic strategies to up-regulate DAB2IP and restore the tumor suppressor's presence within the neoplastic cells, or by targeting downstream effectors such as clusterin (26) .
This pilot study gives us a rationale to consider further validation study of DAB2IP and EZH2. Disabled homolog 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 3 Although NU7441 has demonstrated excellent radiosensitization both in vitro and in vivo, this compound is limited by its poor solubility in water and reduced oral bioavailability. 4 Therefore there is an urgent need for alternative methods that facilitate localized NU7441 delivery for effective radiosensitization.
In recent years there has been a push for localized therapy in hopes of reducing normal tissue effects as well as limiting side effects of the treatment. Nanoparticles (NPs) have become central players in the localized therapy push. NPs have been used successfully as radiation sensitizers; specifically, several studies have shown that gold can radiosensitize prostate cancer cells by arresting the cell cycle into G2/M. 5 Similarly, Jin et al. 6 have synthesized poly lactic-co- A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   4 the prostate cancer cells have not been studied so far. Also, there have been no studies to the authors' knowledge on the development of NU7441-incorporated NPs for the potent radiosensitization of prostate cancers.
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Therefore in this study, multifunctional PLGA-based NPs were synthesized for sustained release of NU7441 for targeted radiosensitization of prostate cancer cells. The FDA-approved biocompatible and biodegradable PLGA is a commonly used polymer in drug delivery and is known to provide a sustained release of the encapsulated agent over time both by degradation and diffusion. 7 Iron oxide NPs were incorporated as contrast agents for Magnetic Resonance Imaging (MRI), for magnetic targeting and also to induce hyperthermia in the tumor using an external alternating magnetic field. 8, 9 To increase the target specificity of PLGA particles, the particles were further conjugated with R11-a polyarginine cell permeable peptide with prostate specificity, 10 to form R11-NU7441 NPs. Studies conducted previously have already shown that the R11 peptides have higher specificity and uptake efficiency by prostate cancer cells in comparison with other cell-penetrating peptides such as TAT, KALA, penetratin and L-lysine K11. 11 Further, we have also previously demonstrated the significantly higher accumulation of R11-conjugated thermoresponsive NPs in the prostate tumor of NOD SCID mice, compared to other vital organs. 12 In this study, R11-conjugated PLGA-based NPs containing NU7441 were synthesized to selectively enhance the radiation sensitivity of prostate cancer cells.
MATERIALS AND METHODS
Preparation of R11-conjugated, NU7441-loaded NPs
The PLGA magnetic NPs (PLGA-MNPs) were prepared using a single emulsion technique in which PLGA (Lakeshore Biomaterials, Birmingham, AL), bare iron oxide NPs peptide was added and the solution was kept for shaking at room temperature overnight. The sample was washed and freeze-dried to obtain R11-conjugated NPs.
Characterization studies
Dynamic light scattering (DLS) (ZetaPals Analyzer, Brookhaven Instruments, Holtsville, NY ) was used to study the size, surface charge and zeta potential of unconjugated and R11- A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   6   observation of NP morphology using Transmission Electron Microscopy (TEM, FEI Tecnai G2 Spirit BioTWIN, Hillsboro, OR). Further, Fourier Transform Infrared spectroscopy (FTIR, Bruker VECTOR 22 spectrometer, Madison, WI) was used to determine the successful conjugation of R11 and incorporation of iron oxide within the PLGA NPs. Iron content was determined based on a standard iron assay as described previously. 13 Briefly, the NP solution was incubated with 30% (v/v) hydrochloric acid at 55 o C for 2 h. Then ammonium persulfate (APS, 1mg/ml) and potassium thiocyanate (0.1 M) was added consecutively to the solution followed by 15 mins shaking. The iron concentration in the NPs was determined by obtaining absorbance readings at 520 nm, which was compared against iron oxide NP standards. A superconducting quantum interference device (SQUID, Quantum design, CA) magnetometer was also used to study the superparamagnetic behavior of iron oxide-encapsulated NPs. Briefly, the NPs were embedded in an epoxy gel and mounted on the instrument using a plastic straw. The behavior of the NPs in response to changing magnetic field at room temperature was determined.
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Following initial characterization, the NPs were further studied for their stability and drug release kinetics. The NPs were suspended in de-ionized (DI) water and 10% Fetal bovine serum (FBS) in RPMI 1640 media for a period of 5 days at 37 o C and particle size was measured A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   7 2.3.
In vitro toxicity study
To study the toxicity of our NPs, a 96-well plate was first seeded with immortalized human prostate epithelial cells, PZ-HPV-7 at a seeding density of 15,625 cells/cm 2 
Rate of cellular uptake of NPs
The dose-and magnetic field-dependent uptake of unconjugated NPs and R11-NU7441
NPs by PC3 prostate cancer cells was assessed in the presence and absence of a 1.3 Tesla (T) magnet. The cells were seeded at a density of 12,631 cells/cm 2 in a 48-well plate and allowed to grow for 24 hours. The PC3 cells were seeded at lower seeding density to ensure that these rapidly dividing cells do not become overconfluent and die due to insufficient growth area, for the duration of the experiment. A 96 wellplate was used for cytotoxicity study above as only one assay (MTS assay) was required to be conducted for this study. For cellular uptake study, a greater volume of cell lysis samples was required as 2 assays (iron assay and BCA protein assay)
were to be conducted to determine the amount of NPs and the amount of cell/ total protein per 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   8 well. Therefore the 48 wellplate was used so that sufficient sample would be available for analysis. Following 24 hour incubation, the PC3 cells were exposed to increasing concentration of NP suspension (0, 100, 200, 300, 500, 1000 µg/ml) in media and incubated for 2 hours. To study magnetic field-dependence of uptake, the well-plate was placed directly above a 1.3 T external magnet to ensure that the cells are uniformly exposed to the magnetic field. These cells were then incubated at 37 o C for 2 hours. The following day, the media was aspirated and the cells were washed with phosphate buffered saline (PBS) before being lysed using 1% Triton X-100. The iron oxide present within the cells was quantified using iron assay as explained previously. 13 A Pierce BCA protein assay was also performed to determine the amount of cell protein per well for normalization of iron oxide taken up by the cells.
Colony Formation Assay
Exponentially growing prostate and lung cancer cells were treated with either control or R11-NU7441 NPs for 4 hours in the absence of a magnet. After incubation, cells were washed and then treated with increasing doses of ionizing radiation (IR) (0, 2, 4, 6, and 8 Gy). Cells were then trypsinized and counted using a particle counter (Beckman Coulter, Inc., Brea, CA), diluted serially to appropriate concentrations and plated into 60-mm dish in triplicate. After 7 to 14 days of incubation, the colonies were fixed and stained with 4% formaldehyde in PBS containing 0.05% crystal violet. Colonies containing >50 cells were counted. Surviving fraction was calculated as (mean colony counts)/[(cells plated) × (plating efficiency)], in which plating efficiency was defined as (mean colony counts)/(cells plated for unirradiated controls). The data are presented as the mean ± SD of at least three independent experiments. The curve S = e − (αD + βD2) was fitted to the experimental data using a least square fit algorithm and the program Sigma 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   9 Plot (Systat Software, Inc., San Jose, CA). The radiation dose enhancement ratio (DER) was calculated as the dose (Gy) for radiation alone divided by the dose (Gy) for radiation plus drugs (normalized for drug toxicity) for a surviving fraction of 0.25.
DNA Double Strand Break Repair Assay
DSB repair assay was performed by counting phospho-γH2AX foci after IR, NP and IR+NP treatment. These cells were plated on poly-lysine-coated coverslips, were allowed to attach overnight and then treated with either control or R11 conjugated NU7441 NPs for 4 hours in the absence of a magnet, followed by washing with PBS and irradiated at 2 Gy. Cells were fixed in 4% formaldehyde/PBS for 30 minutes, permeabilized in 0.5% Triton X-100 in PBS for 1 hour, and blocked in 5% bovine serum albumin and 1% normal goat serum for 1 hour at room temperature. Then, cells were incubated with the primary antibody, anti-phospho-Histone γH2AX (Ser139; 1:2,000) for 1 hour. Rhodamine red-conjugated goat anti-mouse was used as secondary antibodies. Cells were mounted in a Vectashield mounting medium containing 4′, 6diamidino-2-phenylindole (DAPI). Phospho-γH2AX foci were examined using a fluorescence microscope (CRG Precision Electronics, Houston, TX). The number of phospho-γH2AX foci was determined at each time point (average of 100 nuclei), and the percentage foci remaining was plotted against time to obtain DSB repair kinetics. Data is represented as mean ± SEM.
RESULTS
Characterization of R11-NU7441 NPs
An average diameter of 265.5+ 64.0 and 274.13+ 79.96 nm was observed for the unconjugated NPs and R11-conjugated NU7441 NPs respectively. The polydispersity values in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 the range of 0.12-0.l6 indicated that the particles are uniformly dispersed with minimal size variation. Additionally, high zeta potential values of -17.39 + 0.58 and -24.52 + 0.54 indicated that both the conjugated and non-conjugated NPs are very stable and do not aggregate. The TEM images concurred with DLS results and indicate that our NPs are spherical in shape with iron oxide presented in the particles (Fig. 1A) . Iron assay results indicated the presence of 8.44% iron content within our R11-NU7441 NPs, which could be attracted towards an external magnet (1.3T) (Fig. 1B) .
The NPs were further characterized for the presence of functional groups that can confirm peptide conjugation and inclusion of iron oxide, using Fourier Transform Infrared spectroscopy (FTIR). The peak at ~ 590 cm -1 confirms presence of Fe-O group. The NH 2 peak at 1420 cm -1 and NH peak at 1500 cm -1 is characteristic of Arginine present in R11 peptide indicating successful R11-conjugation. The CH 2 (2850 cm -1 ) and C=O peaks (1740 cm -1 ) are characteristic of PLGA. The C=O peak can also represent O=C-N-H bond formed during EDC-NHS chemistry for R11 conjugation (Fig. 1C) . Further, analysis of SQUID measurements indicated that our particles maintained their superparamagnetic behavior although a decrease in saturation magnetization to 48.64 emu/g was observed (Fig. 1D) . A remanence and coercivity of 6.21 (Mr/Ms) and 85.009 Oe respectively was observed for the NPs in comparison to 6.7
(Mr/Ms) remanence and 75.556 Oe coercivity of bare iron oxide NPs.
Results from the stability studies showed that there was no statistically significant change in particle size of the R11-NU7441 NPs in DI water and 10% FBS over a period of 5 days (Fig.   2 ). This indicates that our particles are relatively stable and are not expected to aggregate under physiological conditions. A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   11 
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Drug loading and release kinetics
The release of NU7441 from our NPs was monitored over a period of 21 days. The particles showed a loading efficiency of 51.89% for NU7441. A burst release of about 41% of the encapsulated drug was observed within 1 day of the study, followed by sustained release of 90.48% of the encapsulated NU7441 from the NPs within 3 weeks (Fig. 3 ).
3.3.
In vitro cell studies on R11-NU7441 NPs
Cytocompatibility studies showed greater than 80% PZ-HPV-7 viability up to an NP concentration of 1000 µg/ml (Fig. 4A ). Viability at 2000 µg/ml concentration was significantly less than the control group, although ~80% of the cells were still viable. This demonstrates that our R11-NU7441 NPs are cytocompatible with no toxic effects observed even at a high concentration of 1000 µg/ml.
Further, cellular uptake of unconjugated NPs by PC3 cells in the presence of a magnet was found to be significantly lower than uptake of R11-NU7441 NPs both in the presence and absence of a magnet. All particles were taken up by PC3 cells in a dose-dependent manner;
however, the highest uptake was observed for R11-conjugated NPs in the presence of an external magnetic field (1.3T) (Fig. 4B ). This indicates that although R11 conjugation significantly improves NP uptake by PC3 cells, an external magnetic field can facilitate greater cellular uptake of the R11-NU7441 NPs.
DNA DSB Repair Kinetics
To test both the efficacy and specificity of R11-NU7441 NPs, both lung and prostate cancers were treated with NPs to determine the specificity of R11 targeting and the efficacy of A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 NU7441 release. In H460, a non-small cell lung cancer cell line, treatment with R11 conjugated NPs and radiation did not result in decreased DNA DSB repair kinetics (Fig. 5A ). However, in PC3, a prostate cancer cell line, treatment with R11 conjugated NPs and radiation resulted in significantly slower DNA repair kinetics (Fig. 5B) . The results of this experiment imply that R11-NU7441 NPs will specifically target prostate cancer cells and also radiosensitize these cells.
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Colony Formation Assay
To further explore the radiosensitizing ability of R11-NU7441 NPs, lung and prostate cancer cells were treated with radiation and a dummy particle containing no NU7441 or radiation and R11-NU7441 NPs. As with the DNA DSB break repair assay H460 cells show no radiation sensitization ( Fig. 6A ), while PC3 cells show a prominent radiation sensitizing effect (Fig. 6B ).
DISCUSSION
Recent years have shown a growing interest and demand for multifunctional A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   13 PLGA NPs have played key roles in radiation sensitization of cervical and breast cancer cells using a combination of drugs. 6, 16 Although the average diameter of our R11-NU7441 NPs is >200 nm, particles in this size range have been used previously by other groups for cancer therapy. For example, Alendronatecoated PLGA-iron oxide NPs (235 nm) were synthesized by Thamake et al. 17 for specific targeting of bone metastasis of breast cancer. In vivo studies on athymic female nude mice demonstrated that these particles showed high localization to the bone and could significantly reduce tumor-induced bone resorption as well as tumor growth rate. Our lab has also previously synthesized core-shell NPs of 296 nm diameter for melanoma targeted therapy. These particles showed significantly higher localization than unconjugated NPs, in the tumor of B16F10 melanoma orthotopic mouse model indicating that they can be used for targeted melanoma therapy. 18 Our particles also maintained the superparamagnetic behavior of iron oxide, although a slight decrease in saturation magnetization (48.64 emu/g) is noted in R11-NU7441 NPs. This result is expected due to the presence of the polymer which tends to generate a diamagnetic moment in response to the applied magnetic field. 18, 19 However, NPs having similar or lower magnetization values have been used previously for various drug delivery applications with some degree of success, 20, 21 indicating that our particles remain within the range suitable for targeted drug delivery. Our stability study results concur with previous studies on PLGA NPs showing good stability and minimal aggregation over a period of 5 days. 22 Also, the drug release kinetics of our particles showed a sustained release similar to that obtained by Jia et al. 23 In their study, doxorubicin-loaded PLGA-MNPs showed a burst release for the initial first day followed by sustained release for 7 days. This characteristic bi-phasic release was also observed in curcumin- A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14
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Following the physical and chemical characterization of our R11-NU7441 NPs, in vitro studies were carried out to study cytocompatibility and cellular uptake in the presence or absence of a magnet. Greater than 80% PZ-HPV-7 viability was observed when incubated with all NP concentrations, which is in agreement with previous studies demonstrating the cytocompatibility of PLGA NPs with LAG mouse fibroblast connective tissue 24 and 3T3 fibroblasts. 25 Additionally, dose-dependent cellular uptake of our NPs by PC3 cells was observed, similar to observations by Akbarzadeh et al. 26 and Davda et al. 27 using Folate-PLGA-PEG NPs. The significantly higher magnetic-field dependent uptake of our particles by PC3 cells agrees with results obtained by Wadajkar et al., 28 where their biodegradable photoluminescent polymer (BPLP)-coated iron oxide NPs were also significantly uptaken by PC3 in the presence of a 1.3T magnet. The R11 conjugation onto the surface of our NPs also played a key role in active targeting and uptake of NU7441-loaded particles by prostate cancer cells. Our results concur with studies by Patel et al. 29 which showed higher dose-dependent uptake of R11-conjugated PLGA NPs by PC3 cells when compared to NPs conjugated with folic acid and RGD-4C.
Previously, we have demonstrated preferential uptake of R11 peptide by the prostate cancer cells and prostate tissues. 30, 31 In addition, Hao et al. 30 performed a comparative PET-CT imaging experiment by using prostate (PC3) and lung (H2009) tumor-bearing mouse models and confirmed that the absolute uptake of 64 Cu-DOTA-NHGR11 in the PC3 tumors was significantly higher than in the lung (H2009) tumors throughout the imaging study. Using the colony formation assays, we show that R11-NU7441 NPs radiosensitize only prostate cancer cell lines.
Furthermore, this enhanced radiation sensitivity in prostate cancer cells can be attributed to slower rate in DNA DSB break repair process due to the preferential uptake of R11-NU7441
NPs in prostate cancer cells. A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 15
In addition to the targeted delivery of radiosensitizers to prostate cancer cells presented in this work, NPs encapsulating radiosensitizers have also been used for other various cancer cells.
For example, HeLa and MCF-7 have been successfully radiosensitized using PLGA NPs containing the hypoxic radiosensitizer etanidazole (SR-2508). 6 Similarly, PLGA NPs loaded with paclitaxel, which acts as both an anti-cancer drug as well as a radiosensitizer, has been effectively used in vitro against MCF-7 cells. 32 A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 16
CONCLUSIONS
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